Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

PI3K activation in neural stem cells drives tumorigenesis which can be ameliorated by targeting the cAMP response element binding protein

A novel mouse model for glioma demonstrating that the PI3K pathway is important for initiation of tumorigenesis

Research

Most clinical anti-EGFR antibodies do not neutralize both wtEGFR and EGFRvIII activation in glioma

We discovered a previously unknown major resistance mechanism in glioma in that most EGFR domain III-targeting antibodies do not neutralize EGFRvIII

Research

Kids are not small adults, Identifying age-dependent drug targets in paediatric oncology

Cancers in children are very different to cancers in adults. However, most therapeutic strategies are designed explicitly for adult cancers, and then used in children if proven safe.

Research

The interplay between sarcoma and surgery-induced wound healing

In this project, we are using systems biology approaches to map the wound healing response in sarcoma following surgery to identify new treatments that can prevent sarcoma relapse.

Research

Timing of excision after a non-severe burn has a significant impact on the subsequent immune response in a murine model

Early excision of the wound, during the phase of immune down-regulation initiated by the burn, maintains an innate and adaptive immune cell response

Research

Making a Killer: Selecting the Optimal Natural Killer Cells for Improved Immunotherapies

Over the past 20 years natural killer (NK) cell-based immunotherapies have emerged as a safe and effective treatment option for patients with relapsed or refractory leukemia. Unlike T cell-based therapies, NK cells harbor an innate capacity to eliminate malignant cells without prior sensitization and can be adoptively transferred between individuals without the need for extensive HLA matching.

Research

Immune checkpoint therapy responders display early clonal expansion of tumor infiltrating lymphocytes

Immune checkpoint therapy (ICT) causes durable tumour responses in a subgroup of patients, but it is not well known how T cell receptor beta (TCRβ) repertoire dynamics contribute to the therapeutic response. 

Research

Celebrating 100 years of Immunology & Cell Biology – a special focus on the field of tumor immunology in Australia

In this Commentary article, as part of the 100-year celebrations of the journal, we reflect on the contribution of articles published in ICB in the field of tumor immunology. A highlight is a series of interviews conducted with three Australian-based ICB authors who have contributed key papers over the years: Rajiv Khanna, Delia Nelson and Ian Frazer.

Research

Cancer chemotherapy: insights into cellular and tumor microenvironmental mechanisms of action

Chemotherapy has historically been the mainstay of cancer treatment, but our understanding of what drives a successful therapeutic response remains limited.

Research

Experience of patients with lung cancer and with targeted therapy-related skin adverse drug reactions: A qualitative study

To explore the experience of non-small-cell lung cancer patients with targeted therapy-related skin adverse drug reactions.